Corrigendum to “Isoalantolactone/hydroxamic acid hybrids as potent dual STAT3/HDAC inhibitors and self-assembled nanoparticles for cancer therapy” [Euro. J. Med. Chem. (2024) 116765]

IF 6 2区医学 Q1 CHEMISTRY, MEDICINAL

European Journal of Medicinal Chemistry Pub Date : 2025-01-26 DOI:10.1016/j.ejmech.2025.117307

Hualong Mo, JieYing Liu, Zhengxi Su, Deng-Gao Zhao, Yan-Yan Ma, Kun Zhang, Qi Wang, Chun Fu, Yao Wang, Meiwan Chen, Burong Hu

引用次数: 0

Abstract

The authors regret to inform that in Fig. 9, the same TUNEL staining image was used for the control group and the 18 (2.5 mg/kg) group. We have replaced it with the correct image. Correct forms are listed below.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Medicinal Chemistry 化学-医药化学

CiteScore

11.70

自引率

9.00%

发文量

863

审稿时长

29 days

期刊介绍： The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers. A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.